Abstract

Nonmelanoma skin cancers (NMSCs) in ruxolitinib-treated patients with myeloproliferative neoplasms behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis. Vigilant skin assessment, counseling on NMSC risks, and prospective ruxolitinib-NMSC studies are crucial.

Subjects:
Clinical Trials and Observations, Myeloid Neoplasia
1.
Jalles
C
,
Lepelley
M
,
Mouret
S
,
Charles
J
,
Leccia
MT
,
Trabelsi
S
.
Skin cancers under Janus kinase inhibitors: a World Health Organization drug safety database analysis
.
Therapie
.
2022
;
77
(
6
):
649
-
656
.
Google Scholar
Crossref
Search ADS
PubMed
 
2.
Lin
JQ
,
Li
SQ
,
Li
S
, et al.
A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis
.
J Am Acad Dermatol
.
2022
;
86
(
2
):
339
-
344
.
Google Scholar
Crossref
Search ADS
 
3.
Blechman
AB
,
Cabell
CE
,
Weinberger
CH
, et al.
Aggressive skin cancers occurring in patients treated with the janus kinase inhibitor ruxolitinib
.
J Drugs Dermatol
.
2017
;
16
(
5
):
508
-
511
.
Google Scholar
PubMed
 
4.
Maffioli
M
,
Giorgino
T
,
Mora
B
, et al.
Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients
.
Blood Adv
.
2019
;
3
(
21
):
3196
-
3200
.
Google Scholar
Crossref
Search ADS
PubMed
 
5.
Jakavi 10mg tablets: summary of product characteristics (SmPC). electronic medicines compendium (emc)
. Accessed 31 July 2023. https://www.medicines.org.uk/emc/product/7786/smpc.
6.
Barrett
WL
,
First
MR
,
Aron
BS
,
Penn
I
.
Clinical course of malignancies in renal transplant recipients
.
Cancer
.
1993
;
72
(
7
):
2186
-
2189
.
Google Scholar
Crossref
Search ADS
PubMed
 
7.
Schmults
CD
,
Karia
PS
,
Carter
JB
,
Han
J
,
Qureshi
AA
.
Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study
.
JAMA Dermatol
.
2013
;
149
(
5
):
541
-
547
.
Google Scholar
Crossref
Search ADS
PubMed
 
8.
Brougham
NDLS
,
Dennett
ER
,
Cameron
R
,
Tan
ST
.
The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors
.
J Surg Oncol
.
2012
;
106
(
7
):
811
-
815
.
Google Scholar
Crossref
Search ADS
 
9.
Thompson
AK
,
Kelley
BF
,
Prokop
LJ
,
Murad
MH
,
Baum
CL
.
Risk factors for cutaneous squamous cell carcinoma outcomes: a systematic review and meta-analysis
.
JAMA Dermatol
.
2016
;
152
(
4
):
419
-
428
.
Google Scholar
Crossref
Search ADS
PubMed
 
10.
Tam
S
,
Yao
CMK
,
Amit
M
, et al.
Association of immunosuppression with outcomes of patients with cutaneous squamous cell carcinoma of the head and neck
.
JAMA Otolaryngol Head Neck Surg
.
2020
;
146
(
2
):
128
-
135
.
Google Scholar
Crossref
Search ADS
PubMed
 
11.
Lee
GH
,
Guzman
AK
,
Divito
SJ
,
Soiffer
RJ
,
Silk
AW
,
Schmults
CD
.
Cutaneous squamous-cell carcinoma after treatment with ruxolitinib or belumosudil
.
N Engl J Med
.
2023
;
389
(
2
):
188
-
190
.
Google Scholar
Crossref
Search ADS
 
12.
Aboul-Fettouh
N
,
Nijhawan
RI
.
Aggressive squamous cell carcinoma in a patient on the Janus kinase inhibitor ruxolitinib
.
JAAD Case Rep
.
2018
;
4
(
5
):
455
-
457
.
Google Scholar
Crossref
Search ADS
PubMed
 
13.
Mohsin
N
,
Whitecar
SB
,
Jones
J
,
Childs
JM
,
Brownell
I
.
Development of sebaceous carcinoma in a patient on ruxolitinib therapy
.
JAAD Case Rep
.
2022
;
26
:
17
-
19
.
Google Scholar
Crossref
Search ADS
PubMed
 
14.
Polverelli
N
,
Elli
EM
,
Abruzzese
E
, et al.
Second primary malignancy in myelofibrosis patients treated with ruxolitinib
.
Br J Haematol
.
2021
;
193
(
2
):
356
-
368
.
Google Scholar
Crossref
Search ADS
PubMed
 
© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
2024
You do not currently have access to this content.
Sign in via your Institution